Introduction
Intercellular adhesion of B cell chronic lymphocytic leukemia (B-CLL) cells is relevant for the pathophysiology of the B-CLL disease. Migration of B-CLL cells through the peripheral blood, selective adhesion to endothelial cells and traffic through primary and secondary lymphoid organs is determined by a set of functionally relevant adhesion molecules. Differential usage of these adhesion pathways by B-CLL cells also seems to have an important impact on the clinical presentation of B-CLL. Members of the integrin family of adhesion molecules are differentially expressed in lymphoid leukemias. [1] [2] [3] [4] [5] Expression of ␤1, ␤2 and ␤3 integrins on B-CLL cells correlates with worsening of the prognosis of the disease. 2 In addition, sera of patients with acute leukemia contain elevated concentrations of secreted vascular cell adhesion molecule-1 (VCAM-1) 6 and levels of secreted ICAM-1 correlate with progression of B-CLL. 7 It is currently unknown, however, how these different adhesion pathways guide the traffic of B-CLL in lymphoid organs and how they determine the intercellular adhesion of the leukemic cells.
The current study aims at defining the adhesion molecules that are responsible for the binding of B-CLL cells to distinct histologic compartments of normal lymphoid tissues in situ. Furthermore, we sought to identify the structures on B-CLL cells that regulate the homotypic aggregation of these cells. B-CLL cells were found to bind via the ligand pair integrin ␣4␤1/vascular cell adhesion molecule-1 (VCAM-1) selectively to the germinal centers of secondary lymphoid follicles.
Engaging CD19 on B-CLL cells specifically induced homotypic aggregation through the ligand pair integrin ␣ L (leukocyte function antigen-1 (LFA-1),CD11a)/intercellular adhesion molecule-1 (ICAM-1) and through CD21. We speculate that these adhesion mechanisms influence the migration and metastasis of B-CLL cells in vivo.
Materials and methods

B-CLL samples and cell culture
B-CLL cells were isolated by Ficoll gradient centrifugation from the peripheral blood of B-CLL patients (n = 33) after obtaining informed consent. All studies were approved by the Ethics Committee of the Virchow Hospital of the Humboldt University. Samples were only used from patients who had not received chemotherapy within the previous 3 weeks. Disease stages were defined according to Rai et al. 8 Purity and phenotype pattern of the B-CLL samples were characterized by flow cytometry (FacScan; Becton Dickinson, Heidelberg, Germany). Diagnosis of the CLL cases was confirmed by examining co-expression of CD5, CD19, CD23 and surface immunoglobulin (slg). B cells from the peripheral blood of normal healthy donors were prepared by Ficoll gradient centrifugation and elimination of T lymphocytes by rosetting with sheep red blood cells. For in vitro culture, cells were maintained at 5% CO 2 in RPMI-1640 medium supplemented with 10% FCS, 1% glutamine and 1% penicillin/streptomycin.
Effect of mAbs on proliferation and on apoptosis of CLL cells was investigated by culturing cells (1 × 10 6 /ml) for 72 and 48 h, respectively, with various antibodies (5 g/ml) and with tetradecanoyl phorbol acetate (TPA; 0.005 g/ml) and dexamethasone (100 ng/ml) as controls. Stimulation of cells was quantified using a nonradioactive detection assay according to the instructions of the manufacturer (EZ4U; Biomedica, Vienna, Austria) and an ELISA reader. This assay quantifies cell proliferation by determining the capability of the mitochondria to reduce uncolored tetrazolium salts (MTT) into intensely coloured formazan derivatives. 9 Quantification of apoptosis and necrosis was performed by flow cytometric analysis of CLL cells labeled with Annexin-V-FITC 10 (Bender MedSystems, Vienna, Austria) and with propidium iodide, respectively.
Reagents and monoclonal antibodies (mAbs) mAbs against the following antigens were obtained from Dianova-Immunotech (Hamburg, Germany): CD3 (clones X35 and UCHT-1), CD5 (BL1a), CD11a (integrin ␣ L (25.3.1)) , CD18 (7E4), CD19 (J4.119), CD20 (B9E9/HRC20), CD21 (BL13), CD26 (BA5), CD29 (K20), CD49b (integrin ␣2 (Gi9)), CD49c (integrin ␣3 (M-KID 2)), CD49d (integrin ␣4 (HP2/1)), CD54 (ICAM-1(84H10)), CD58 (LFA-3 (AICD58)), CD102 (ICAM-2 (B-T1)), CD77 (38-13), CD81 (JS64) and CD106
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(VCAM-1 (1G11)). All mAbs were used at a concentration of 10 g/ml unless otherwise indicated. Fluorescein isothiocyanate (FITC-conjugated mouse IgM (Dako, Glostrup, Denmark) served as a negative control for flow cytometry. Cycloheximide, herbimycin and propidium iodide were obtained from Sigma (St Louis, MO, USA). Cytochalasin B, genistein and H7 were purchased from Calbiochem (La Jolla, CA, USA). Staurosporine was obtained from Boehringer Ingelheim (Heidelberg, Germany).
Frozen section binding assay
To study adhesion of B-CLL cells to tonsils in situ, an in vitro frozen section assay was performed with modifications. [11] [12] [13] [14] [15] [16] Normal human tonsils, obtained from routine tonsillectomies, were snap frozen, cut (8 m), placed on microscope slides and dried overnight. B-CLL cells were applied at 2.4 × 10 7 cells/ml in 300 l adhesion medium (containing 2.4 mM MgCl 2 ) on tissue sections within a 2-cm diameter circle marked with a water-repellent 'Pap-pen' (Dako, Carpinteria, CA, USA) and were incubated under rotation (70 revolutions per min) for 20 min at room temperature. Rotation was used since under static conditions no specific binding to histologic compartments was noted (not shown). Thereafter, slides were decanted, were fixed for a minimum of 5 h in fresh, cold 3%-glutaraldehyde/PBS and were counterstained with hemalaun. Bound cells were identified by light microscopy (×250). To determine adhesion molecules involved in the tissue binding, B-CLL cells were incubated with a set of mAbs, washed and examined for reduced tissue adherence. To block corresponding adhesion molecules on the tissue, tonsils were incubated with mAbs and washed prior to applying the cells. Decrease of binding was assessed in at least three separate experiments by comparison with the adhesion of cells treated with isotypematched control mAbs. Cell binding was morphometrically quantified with digitalized, video-supported light microscopy using a Zeiss Axioplan microscope (Jena, Germany) and the ISIS 3 software (MetaSystems, Belmont, MA, USA). Inhibition of binding was scored as positive (complete inhibition of binding) and negative (no reduction of cell binding).
Homotypic adhesion assay
To determine induction of homotypic aggregation of B-CLL cells and normal B cells by mAbs, we used a modified method described by Rothlein et al. 17 Cells (2 × 10 6 cells/ml) were cultured at 37°C and 5% CO 2 with a series of different mAbs (5 g/ml) in duplicates in flat-bottom 96-well microtiter plates. Isotype-matched mAbs were used as negative controls. Aggregate formation was determined by inverse light microscopy after 24 h. Homotypic adhesion was qualitatively scored as positive (all cells formed aggregates) and negative (no aggregates).
To determine cell surface molecules involved in the mAbinduced homotypic adhesion, B-CLL cells were treated as above with mAbs for 24 h, washed, resuspended and allowed to reaggregate at 37°C for 24 h in media containing a second set of different mAbs. Reduction of adhesion was determined by comparison with reaggregations in media with isotype control mAbs and was qualitatively scored as positive (inhibition of cluster formation) and negative (no inhibition of cluster formation).
The involvement of intracellular pathways in mAb-induced homotypic aggregation of B-CLL cells was determined using different inhibitors as described. 12 B-CLL cells (2 × 10 6 /ml) were incubated for 30 min at 37°C with 5% CO 2 in media containing 10 2 nM staurosporine, 50 M H7, 50 mg/ml genistein, 10 g/ml cycloheximide, 1 g/ml herbimycin, 0.1 mM cytochalasin B or were treated with control media. Control media had the same concentrations of DMSO solvent as were used in media-containing inhibitors. Cells were subsequently washed, were treated as described above with mAbs and were examined for reduced homotypic aggregation.
Statistical analyses
Significance of differences of the expression of cell surface molecules was determined using the Mann-Whitney U test. Significance of difference between binding pattern of CLL cells of patients with low (0-II) and high (III and IV) Rai stages was determined using the Fisher exact test.
Results
Adhesion of B-CLL cells to germinal centers of human tonsils via integrin ␣4␤1/VCAM-1
To determine the in situ binding pattern of B-CLLs on secondary lymphoid tissues, an adhesion assay on human tonsils was performed. Of 14 different cases examined, CLL cells of seven patients bound selectively to the germinal centers of tonsils ( Figure 1 ). Binding B-CLL samples and cells that failed to adhere differed in the patients' stages of the disease (Table 1) . In contrast to the cases with non-binding B-CLL cells, most patients whose CLL cells showed adhesion had advanced stages of their disease (Rai III and IV; P = 0.029). In addition, binding B-CLL cells expressed integrin ␣4, whereas cells that did not adhere were almost negative for this adhesion molecule (P = 0.0017; Figure 2 ). In contrast, differential expression of integrin ␣ L , an antigen involved in germinal center binding of T lymphocytes, 16 did not correlate with the binding pattern of the CLL cells. To define the binding structures responsible for the in situ adhesion, mAbs were incubated with the B-CLLs and were tested for their ability to inhibit tissue adherence. Among a large panel of mAbs against adhesion molecules (CD11a, CD18, CD29, CD49b, CD49c, CD49d, CD54, CD58, CD102, CD106) only antibodies against integrin ␣4 (CD49d) and against the corresponding ␤1 chain (CD29) were able to block binding of B-CLL cells. When tonsils were incubated with a mAb against a ligand of integrin ␣4␤1, VCAM-1, binding was inhibited, whereas a negative control mAb did not impair germinal center binding.
Homotypic adhesion of B-CLL cells transmitted via CD19
In order to identify mechanisms regulating the adhesion between B-CLL cells, we investigated aggregate formation of B-CLL cells induced by engaging cell surface antigens using a panel of different mAbs. Only mAbs against the CD19 antigen were able to provoke homotypic aggregation of B-CLL cells. Antibodies against other antigens expressed on CLL cells did not induce homotypic adhesion (CD5, CD11a, CD20, CD21, CD22, integrin ␤1, CD40, CD49c, integrin ␣4, ICAM-1, CD81 and ICAM-2). Cluster formation was detected in 32 a b
Figure 1
Binding of B-CLL cells to germinal centers of human tonsil sections via integrin ␣4. B-CLL cells were incubated without prior treatment (a) and with prior treatment with anti-integrin ␣4 mAb (b) under rotation on dried tonsil sections. Binding and inhibition of adhesion was assessed by light microscopy (×250). Phenotypic analyses showed that lack of response to treatment with anti-CD19 in one B-CLL sample was not due to low expression levels of CD19 on these tumor cells (not shown). Interestingly, mAbs against CD21 and TAPA-1, which, together with CD19 and Leu-13, form a functionally important membrane complex on B cells, 18 did not induce homotypic adhesion of B-CLL cells. In contrast to B-CLL cells, normal peripheral blood B cells did not show anti-CD19-specific homotypic aggregation.
Next, we aimed at identifying the adhesion molecules that were involved in the anti-CD19-induced aggregation of B-CLL cells. Cellular clusters of anti-CD19-treated B-CLL cells were dispersed and were examined for reduced reaggregation after in vitro culture with mAbs. As seen in Table 2 , reformation of clusters was observed even in the absence of anti-CD19 mAb. Among a large panel of different antibodies tested only mAbs against integrin ␣ L , ICAM-1 and CD21 were able to inhibit cluster reformation of anti-CD19-treated B-CLL cells. Treatment with anti-CD19 mAb, however, did not lead to an increased expression of the relevant adhesion molecules integrin ␣ L , CD21 and ICAM-1 (not shown). When tested individually, mAbs against integrin ␣ L , ICAM-1 and CD21 blocked aggregation in more than half of the CLL cases examined (Table 2) . Furthermore, combining anti-integrin ␣ L and anti-CD21 inhibited adhesion in all but one CLL case (95%; 18 of 19 cases tested) and anti-ICAM-1 together with anti-CD21 interfered in 79% of the cases (15 of 19 cases examined).
To identify intracellular signals involved in the anti-CD19-induced homotypic aggregation of B-CLL cells, inhibitors of Number of B-CLL cases in which anti-CD19-induced aggregation could be inhibited/total number of cases examined defined intracellular pathways were used. Aggregation triggered by anti-CD19 mAb was blocked by an inhibitor of protein synthesis (cycloheximide), whereas inhibiting protein kinases (staurosporine), protein kinase C (H7), tyrosine kinases (genistein and herbimycin) or the cytoskeleton (cytochalasin B) did not impair homotypic adhesion. These observations indicated that protein synthesis was involved in the anti-CD19-triggered homotypic aggregation of B-CLL cells. Furthermore, to determine the influence of anti-CD19 on the biology of CLL cells, the effect of anti-CD19-treatment on stimulation and apoptosis of B-CLL cells was investigated. However, the effect of anti-CD19 on these parameters did not differ from that of control antibodies (Figure 3 ).
Discussion
The present study describes cellular mechanisms regulating lymphoid tissue binding and homotypic adhesion of B-CLL cells. B-CLL cells specifically bound to germinal centers of tonsils via integrin ␣4␤1/VCAM-1 and triggering via CD19 induced homotypic aggregation of CLL cells via integrin ␣ L /ICAM-1 and CD21. Defining these adhesion pathways might provide help in exploring the pathophysiology of the CLL disease.
A frozen section assay [11] [12] [13] [14] [15] [16] 19, 20 was used to determine whether human B-CLL cells bind to distinct histologic compartments of human tonsils. Previously, clinically relevant data were provided with this assay by demonstrating that the in situ binding pattern of lymphoma cells was an indicator for the capacity of the tumor cells to metastasize in vivo. 21 In addition, adhesion of non-Hodgkin's lymphoma cells to HEV was found to correlate with the clinical manifestation of the disease. 19 The current study demonstrates that in vitro B-CLL cells employ the adhesion molecule integrin ␣4␤1 to bind to VCAM-1 within germinal centers of normal human tonsils. Germinal centers of secondary lymphoid organs are filled with a dense network of antigen presenting follicular dendritic cells (FDCs) 13, [22] [23] [24] which have been identified as ligands for binding of B and T cells in vitro and in situ. [13] [14] [15] [16] 20, 25, 26 Interestingly, in situ binding of CLL cells was not mediated by integrin ␣ L ␤2, although this antigen was differentially expressed by these cells and has been shown to mediate germinal center binding of activated T cells. 16 Possibly, the affinity of integrin ␣ L ␤2 on CLL cells towards their respective ligands was too low to be detected by this assay. Therefore, although mAbs against other integrins did not interfere with Treatment with anti-CD19 mAb has no effect on proliferation or apoptosis of B-CLL cells. Effect of treatment with mAbs and with TPA on proliferation of CLL cells (a). Apoptosis of CLL cells after incubation with mAbs and with dexamethasone (b).
the binding, we cannot completely rule out the possibility that these or other adhesion molecules were involved in the in situ adhesion process. Consistent with previous reports, 14, 16 the result of the binding assay appears to be determined by the extent of the antigen expression and by the affinity of the adhesion molecules. Determining the antigen expression alone, therefore, does not appear to be sufficient for predicting the adhesion pattern in situ.
It may be tempting to speculate that the observed in vitro binding of CLL cells to FDCs of normal lymphoid tissues might reflect the capacity of these tumor cells to invade normal germinal centers via integrin ␣4␤1/VCAM-1. However, histological evaluation of the lymph nodes affected by CLL do not demonstrate infiltrations of germinal centers. Furthermore, the pattern of rearrangement of the immunoglobulin (Ig) heavy and light chain genes and the lack of somatic mutations of the Ig-V region in CLL cells argue against the interpretation that these cells migrate into germinal centers. Yet, VCAM-1 is also selectively expressed by endothelial cells in adult and fetal hematopoietic organs 27 where it mediates the in vitro adherence of normal and leukemic cells. [28] [29] [30] Furthermore, binding on to bone marrow fibroblasts via integrin ␣4␤1/VCAM-1 supported survival of B cell lineage acute lymphoblastic leukemia (ALL) cells. 31 We speculate, therefore, that the observed germinal center binding of B-CLL cells via integrin ␣4␤1/VCAM-1 might mirror the capacity of these cells to use this ligand pair for their migration and proliferation within the microenvironment of hematopoietic organs.
The relevance of the integrin ␣4␤1/VCAM-1-mediated adherence for the pathophysiology of the CLL disease is further strengthened by our observation that expression of integrin ␣4 and germinal center binding via this molecule correlated with advanced disease stages (P = 0.029). Consistent with this are reports that patients with B-CLL cells expressing ␤1, ␤2 and ␤3 integrin chains presented with a poor prognosis and with splenomegaly. 2 The present study identified the molecules on B-CLL cells that influence the intercellular binding of these cells. Among a large panel of mAbs tested, only mAbs against CD19 induced homotypic aggregation of B-CLL cells. Our observation that the clone of anti-integrin ␣4 that was used (HP2/1) did not induce aggregation, was consistent also with the observations of Campanero et al. 32 CD19, together with complement receptor CD21 (CR2), target of an antiproliferative antibody-1 (TAPA-1, CD81) and Leu-13, forms a functionally important membrane complex on B cells. [33] [34] [35] Each component of this complex independently regulates the activation, proliferation and function of B cells 18, 36 and is able to initiate homotypic and heterotypic adhesion. [37] [38] [39] Aggregation of B cells could also be triggered by other cell surface molecules. 40 Our finding that homotypic adhesion of B-CLL cells was induced only by anti-CD19 and not by mAbs against other B cell antigens indicated, in contrast, that CD19 may have a unique role in initiating aggregation of B-CLL cells. The finding that peripheral blood B cells did not show anti-CD19-induced homotypic aggregation is consistent with earlier reports indicating that normal B cells need appropriate stimuli to exert binding in vitro. 13, 14 We identified the adhesion pair integrin ␣ L /ICAM-1 and CD21 as the molecules that mediate the anti-CD19-induced aggregation of B-CLL cells. Interestingly, combinations of these mAbs blocked aggregation in more cases than individual antibodies did. We assume that in some CLL cases the effect of a separate blockade of the two adhesion pathways was too weak to be detected by the aggregation assay. Yet, a combined interference with integrin ␣ L /ICAM-1 and CD21 had a more pronounced negative impact on the anti-CD19-induced aggregation.
The integrin ␣ L /ICAM-1 ligand pair plays a fundamental role in functionally regulating relevant intercellular adhesion processes. [41] [42] [43] Recently, CD21 has been shown to mediate homotypic and heterotypic cell binding of normal B cells and B cell lines through adhesion to its ligand, CD23. [44] [45] [46] Since anti-CD21 but not anti-CD23 impaired the anti-CD19-induced aggregation of B-CLL cells, CD21 appears to employ a ligand different from CD23 for this homotypic adhesion. Treatment with anti-CD19 did not lead to an increased expression of the relevant adhesion molecules. It seems plausible, therefore, that this mAb initiated adhesion by increasing the affinity of the molecules integrin ␣ L , ICAM-1 and CD21. This interpretation is supported by previous findings that integrin-mediated adhesion is mediated by a rapid increase of the affinity of these molecules towards their respective ligands. 14, 47 However, the fact that the anti-CD19-induced aggregation could be blocked by cycloheximide demonstrated that initiation of homotypic adhesion also depended on protein synthesis. The activity of integrin molecules is influenced by a large number of regulatory proteins (reviewed in Ref. 48) . It is possible, therefore, that aggregation of B-CLL cells triggered by anti-CD19 also involves an increase in the expression level of proteins regulating the affinity of integrin ␣ L , ICAM-1 and CD21.
Could the in vitro observed homotypic aggregation of B-CLL cells be relevant for the biology of these cells in vivo? Adhesion of normal B cells and of B cell lines through integrin ␣ L /ICAM-1 leads to proliferation and inhibits apoptotic cell death. [49] [50] [51] [52] In contrast, CD19 is able to initiate cell cycle arrest 53 and apoptosis 54, 55 in B cell lines. However, in this study we did not find evidence that anti-CD19 had a detectable impact on the proliferation or apoptosis of CLL cells. It seems obvious that in contrast to homotypic aggregation induced by anti-CD19 alone, the ultimate fate of B-CLL cells is determined by more complex processes that require additional signalling.
Our descriptions of the mechanisms that regulate heterotypic and homotypic adhesion of B-CLL cells provide ground for hypothetical models that may help to explain some aspects of the B-CLL disease. We propose that the observed germinal center binding of B-CLL cells via integrin ␣4␤1/VCAM-1 reflects the capacity of these cells to migrate and proliferate within the hematopoietic organs. CD19-mediated homotypic aggregation of B-CLL cells via integrin ␣ L /ICAM-1 and CD21 might supply additional signals that modulate the fate of these tumor cells. Future studies will address the question of whether these adhesion pathways are valuable targets for novel immunotherapeutic strategies to treat patients with B-CLL.
